Cessatech AS (XSAT:CESSA) 3-Year Share Buyback Ratio: -10.40% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CESSA Cessatech AS XSAT:CESSA
19 GF Score
Price kr9.10
! 2 Warning Signs
View Full Analysis

What is Cessatech AS 3-Year Share Buyback Ratio?

Cessatech AS XSAT:CESSA -5.21% 19 3-Year Share Buyback Ratio is -10.40 as of Jun. 2026. GuruFocus rates XSAT:CESSA with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,184 Biotechnology companies, Cessatech AS ranks better than 52.11% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cessatech AS's current 3-Year Share Buyback Ratio was -10.40%.

The historical rank and industry rank for Cessatech AS's 3-Year Share Buyback Ratio or its related term are showing as below:

XSAT:CESSA' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -41.8   Med: -26.1   Max: -10.4
Current: -10.4

During the past 6 years, Cessatech AS's highest 3-Year Share Buyback Ratio was -10.40%. The lowest was -41.80%. And the median was -26.10%.

XSAT:CESSA's 3-Year Share Buyback Ratio is ranked better than
52.11% of 1184 companies
in the Biotechnology industry
Industry Median: -11.6 vs XSAT:CESSA: -10.40

Cessatech AS (XSAT:CESSA) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Cessatech AS 3-Year Share Buyback Ratio Related Terms


XSAT:CESSA vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Cessatech AS's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cessatech AS 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cessatech AS's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cessatech AS's 3-Year Share Buyback Ratio falls into.


XSAT:CESSA
19GF Score
Cessatech AS XSAT:CESSA
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cessatech AS 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -10.40 mean?
Cessatech AS (XSAT:CESSA) has a 3-Year Share Buyback Ratio of -10.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cessatech AS and its competitors. According to the industry distribution chart, Cessatech AS ranks #567 out of 1184 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Cessatech AS's 3-Year Share Buyback Ratio too high?
Cessatech AS's current 3-Year Share Buyback Ratio is -10.40. Based on the distribution chart, Cessatech AS ranks #567 out of 1184 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cessatech AS has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #567 out of 1184 companies for 3-Year Share Buyback Ratio. This puts Cessatech AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cessatech AS and its competitors. Cessatech AS's current 3-Year Share Buyback Ratio is -10.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current 3-Year Share Buyback Ratio of -10.40. The current 3-Year Share Buyback Ratio is -10.40. Cessatech AS's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current 3-Year Share Buyback Ratio is -10.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cessatech AS Business Description

Other Exchanges 8GN:Germany
Address Strandvejen 60, Hellerup, DNK, DK- 2900
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
19GF Score

Get the complete analysis for XSAT:CESSA

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.10
Price